Mednet Logo
HomePediatric Hematology/Oncology
Pediatric Hematology/Oncology

Pediatric Hematology/Oncology

Clinical discussions on pediatric blood disorders, childhood cancers, and specialized treatment protocols.

Recent Discussions

What is your preferred strategy for young adults with ITP complicated by recurrent autoimmune neutropenia?

2
3 Answers

Mednet Member
Mednet Member
Hematology · The Mass General Porphyria Center

This is a great question, and I'll say that AIN can be particularly difficult to treat! I'd first ask how low the ANC is and if the patient is presenting with frequent infections/hospitalizations. If not, there may not be a need to treat the AIN (we may just be treating ourselves); oftentimes, there...

What is the best way to prepare children with von Willebrand disease for tonsillectomy to reduce the risk of post-operative hemorrhage?

1 Answers

Mednet Member
Mednet Member
Hematology · University of Pittsburgh Medical Center

I am an adult provider, but the treatment is similar regardless of age. The exact treatment plan will vary depending on the type and severity of VWD (i.e., mild type 1 VWD vs type 2B VWD); however, for tonsillectomies, I provide VWF concentrate 40-80 IU/kg 5-30 min preoperatively, followed by postop...

What is your target Hgb/Hct for women who are pregnant and have sickle cell disease in whom you are doing scheduled transfusions?

2 Answers

Mednet Member
Mednet Member
Pediatric Hematology/Oncology · FibroFighters Foundation

Hg 10-11. My main goal is to suppress reticulocytosis and therefore, the production of more sickled cells.

In what clinical scenario would you consider liver transplant evaluation for a patient with sickle cell hepatopathy?

1 Answers

Mednet Member
Mednet Member
Hepatology · Johns Hopkins Medicine

We have evaluated and transplanted patients with sickle cell hepatopathy with severe liver dysfunction but well-controlled sickle cell. These patients will typically have jaundice, coagulopathy, and biliary strictures. They should not have significant extrahepatic complications of the hematologic di...

At what point would you recommend initiating psychotherapy or psychotropic medications to manage mood and anxiety symptoms following a new oncology diagnosis in pediatric patients?

3
2 Answers

Mednet Member
Mednet Member
Psychiatry · Northwestern Feinberg School of Medicine

Perhaps the most important piece to this question is missing, and that is that more history is required to determine what to do with a recently diagnosed cancer patient. What was the patient’s psychiatric status pre-cancer? If the patient had undiagnosed mental health problems–anxiety or depressio...

In an adult patient with asymptomatic, isolated neutropenia in whom you suspect a Duffy null phenotype, at what ANC or in what situations would you do a bone marrow to look for other etiologies of neutropenia?

4
1 Answers

Mednet Member
Mednet Member
Hematology · Harvard Medical School

What a great question! Happy to answer. As you know, as many as 60% of individuals who have the Duffy null phenotype will have an ANC that is lower than the lower limit of normal in many labs BUT as you also know, the total body (in circulation + in tissues) neutrophil count in such individuals is n...

When would you consider use of emapalumab for HLH/MAS?

1
1 Answers

Mednet Member
Mednet Member
Rheumatology · University of Alabama Birmingham

The FDA has approved emapalumab for familial HLH. For secondary HLH/MAS, I typically begin with anakinra (100 mg q 6 hrs for those 40 kg or more). If this is not enough and if CXCL9 (I send on day one to have the data available) is notably elevated, then consider adding emapalumab. Alternatively, a ...

What criteria is needed in relapsed/refractory B-cell ALL to choose CAR-T therapy over conventional stem cell transplant as destination therapy?

3 Answers

Mednet Member
Mednet Member
Pediatric Hematology/Oncology · Northwestern University Feinberg School of Medicine

Currently, there are no standard criteria used to choose CAR-T over conventional stem cell transplant as destination therapy. However, there are many factors that often push us in one direction or the other. As we learn more about outcomes after CAR-T cell therapy, there are many factors we know are...

What are your top takeaways in Hematologic Malignancies from ASH 2024?

12 Answers

Mednet Member
Mednet Member
Medical Oncology · Virginia Mason Medical Center

Years ago, I was consulting with a patient who had moved to the Pacific Northwest after being diagnosed elsewhere with multiple myeloma. After engaging in initial pleasantries and just before I was about to peel away the specifics of her medical history, she stopped me in my tracks. “Did you go to A...

Do you use G-CSF for a patient with ALL admitted for febrile neutropenia with prolonged count recovery?

2 Answers

Mednet Member
Mednet Member
Hematology · Montefiore

Acknowledging the lack of definitive data, in our group we use G-CSF as primary prophylaxis in adult patients with ALL treated with intensive chemotherapy and hardly ever need to re-administered if they develop FN subsequently. That said, for prolonged neutropenia despite prior G-CSF, we may adminis...